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Mouse strains are either resistant or susceptible to murine cytomegalovirus (MCMV). Resistance is deter-
mined by the Cmv1r (Ly49h) gene, which encodes the Ly49H NK cell activation receptor. The protein encoded
by the m157 gene of MCMV has been defined as a ligand for Ly49H. To find out whether the m157 protein is
the only Ly49H ligand encoded by MCMV, we constructed the m157 deletion mutant and a revertant virus.
Viruses were tested for susceptibility to NK cell control in Ly49H and Ly49H mouse strains. Deletion of the
m157 gene abolished the viral activation of Ly49H NK cells, resulting in higher virus virulence in vivo. Thus,
in the absence of m157, Ly49H mice react like susceptible strains. 129/SvJ mice lack the Ly49H activation NK
cell receptor but express the inhibitory Ly49I NK cell receptor that binds to the m157 protein. The m157
inhibitory phenotype was weak because MCMV encodes a number of proteins that mediate NK inhibition,
whose contribution could be shown by another mutant.
Infection of mice with murine cytomegalovirus (MCMV) is
an established model for studying human cytomegalovirus in-
fection. Immune control of MCMV infection is organized in a
hierarchical and redundant manner by diverse components of
the innate and adaptive immune response (19, 21, 32, 34). NK
cells play an important role in the innate control of cytomeg-
alovirus infection. This has been demonstrated in humans with
a rare disorder characterized by complete absence of NK cells
and in genetically deficient mice lacking NK cells or being
depleted of these cells by treatment with anti-NK cell antibod-
ies (4). On the basis of their susceptibility to MCMV infection,
mouse strains are either susceptible (e.g., BALB/c mice) or
resistant (e.g., C57BL/6 mice) (17, 37). MCMV titers in the
spleens of mice inversely correlate with their ability to mount
an effective NK cell response, which is controlled by the single
dominant locus, named Cmv1, located in the natural killer
gene complex on mouse chromosome 6 (10, 14, 37–39). The
alleles of the Cmv1 locus can confer either susceptibility
(Cmv1s, a recessive allele) or resistance (Cmv1r, a dominant
allele) to MCMV (36, 39).
The Cmv1r (Ly49h) gene encodes the Ly49H receptor (5, 9,
23, 24), which belongs to the Ly49 family of NK cell receptors
and is expressed on approximately 50% of NK cells in C57BL/6
mice (41, 43, 47). Unlike the inhibitory Ly49 receptors, Ly49H
lacks the immunoreceptor tyrosine-based inhibition motif and
is noncovalently coupled with DAP12 at the cell surface, al-
lowing transduction of an activation signal into the cell via its
immunoreceptor tyrosine-based activation motif (16, 43) that
is required for resistance to MCMV (40). However, Ly49H
does not define resistance to vaccinia virus and gammaherpes-
virus 68 (2, 12).
Unlike other members of the Ly49 receptor family, which
use major histocompatibility complex (MHC) class I molecules
as their cellular ligands, Ly49H binds to at least one MCMV-
encoded protein, the m157 gene product (2, 42). The m157
protein has structural homology to MHC class I molecules,
similar to several other proteins encoded by MCMV m145
gene family members (42). An MCMV deletion mutant re-
stricted Ly49H activation to 15 genes in the HindIII-E region
(2). Isolated open reading frames (ORFs) from this region,
with the exception of m157, failed to activate Ly49H. However,
a similar contribution of other genes in this region cannot be
excluded since certain cytomegalovirus proteins encoded by
different genes can only be expressed as a complex (27). There-
fore, it remained an open question whether m157 is the only
viral gene that contributes to MCMV resistance defined by
Ly49H.
To investigate the biological relevance of the m157 gene, we
constructed an m157 deletion mutant, as well as the corre-
sponding revertant virus. We studied the susceptibility of these
recombinant viruses to control by NK cells in vivo in Ly49H
and Ly49H mouse strains. Loss of the m157 gene is associ-
ated with gain of virulence in Ly49H but not in Ly49H
mouse strains. Therefore, m157 is the only MCMV-encoded
protein that activates Ly49H NK cells. The absence of the
gene that encodes this protein in the m157 deletion mutant
gave us the opportunity to reveal the function of viral genes
that down-modulate NK cell activity in Cmv1r mice. Cmv1 has
been defined as a locus of resistance to MCMV, influencing
virus control mainly in the spleen (37). Furthermore, since we
could define m157 as the only MCMV-encoded ligand for the
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Ly49H receptor, we could also address the question of NK cell
control of infection at a different site of infection.
MATERIALS AND METHODS
Viruses and cells. Bacterial artificial chromosome (BAC)-derived MCMV
strain MW97.01 has previously been shown to be biologically equivalent to
MCMV strain Smith (ATCC VR-194, recently reaccessed as VR-1399) and is
here referred to as wild-type (w.t.) MCMV (50). The MS94.5 virus, which
possesses a deletion of 15 genes (m151 to m165) is described elsewhere (46). All
viruses were propagated on third-passage BALB/c mouse embryonic fibroblasts
(MEFs) and purified by sucrose cushion centrifugation. Tissue culture-grown
virus preparations were used for mouse inoculations.
Cells of the mouse macrophage cell line IC-21 were obtained from the Amer-
ican Type Culture Collection (ATCC catalog no. TIB-186) and were grown in
RPMI 1640 medium supplemented with 10% fetal calf serum.
Plasmid construction. Plasmid pori6k-pA, which contains the Zeocin resis-
tance gene, the poly(A) signal from BHG, the origin of replication (ori6k), and
an additional 34-bp FRT site, was generated by ligation of a 353-bp KpnI/PvuII
fragment from plasmid pCDNA4TO (Invitrogen) into the KpnI/EcoRV sites of
plasmid pori6kZeo (A. Bubeck, M. Wagner, Z. Ruzsics, M. Iglesias, I. R. Singh,
and U. H. Koszinowski, submitted for publication). With primers SpeI-nt215895-
918 and SpeI-nt217226-250 and pSM3fr as the template DNA, the m157 gene
and its putative promoter (nucleotide [nt] positions 215895 to 217250, as de-
scribed in reference 33) were amplified by PCR and inserted into the SpeI site of
plasmid pori6k-pA, thereby generating plasmid pori6k-m157-pA. The correct
amplification of the m157 promoter and the m157 gene was confirmed by se-
quencing with primers M157-1 (5-TGTTGACCGCCATCTGTTCTTGA),
M157-2rev (5-GGTAAGATTAATATTCAAGGATCA), and M157-3 (5-GG
ATTGAAAATTGTTACAGCACG) (data not shown).
Insertion of an FRT site into MCMV BAC pSM3fr between genes m16 and
m17. Mutagenesis of the MCMV BACs was performed as previously described
(49). The insertion of a 48-bp FRT site (5-GAAGTTCCTATTCCGAAGTTC
CTATTCTCTAGAAAGTATAGGAACTTC-3) into the intergenic region be-
tween MCMV ORFs m16 and m17 (nt positions 15678 to 15748) was achieved
as follows. A linear PCR fragment containing a kanamycin resistance gene
flanked by two 48-bp FRT sites and viral homologies to the noncoding region
between ORFs m16 and m17 was generated by PCR with primers 5-m16-FRT-
Kan-pCP15 (5-CCCTCTTAATCATGACAATTATAAGTGTCTTATACGCA
ATACTTTTATCATAATTCGGGGGTGTCCAGGGTTTTCCC) and 3-m17-
FRT-Kan-pCP15 (5-GAGGAATAGGAATAACTCACCACCGATTTCAGCGT
CTGCCCCAAGTCTGACTTCCGGCTCGTATGTTGTGTGG) and plasmid
pCP15 (8). This fragment was inserted into pSM3fr by homologous recombination
in Escherichia coli, thereby deleting 70 bp of the noncoding region between these two
genes (nt positions 15678 to 15748). The kanamycin resistance-encoding gene was
subsequently excised by FLP-mediated site-directed recombination as described
previously (49), leaving only one FRT site, which can be used for site-directed
insertion of any gene of interest into this site. The correct mutagenesis of resulting
MCMV BAC pSM3fr-FRT was confirmed by restriction pattern analysis and se-
quencing of the m16-m17 genome region with primers MCMV-15461-down (5-G
AAGTCCATGTATCTCCTTCA) and MCMV-15939-up (5-TCGGACAAATTC
TAAACCTCG) (data not shown). The w.t.-FRT-MCMV strain generated from
pSM3fr-FRT was shown to replicate to w.t. MCMV titers in NIH 3T3 fibroblasts and
also in the lungs, spleens, and livers of BALB/c mice infected with 2  105 PFU at
days 3 and 7 postinfection (data to be published elsewhere). This confirmed that the
insertion of short sequences into this intergenic genome region does not significantly
interfere with virus replication in vitro or in vivo.
Deletion of the m157 ORF in MCMV BACs pSM3fr and pSM3fr-FRT. For
deletion of the m157 ORF in the respective MCMV BACs, a linear DNA
fragment was generated by PCR with primers 5-m157-Kan (5-CGTGGTCAA
GCCGGTCGTGTTGTACCAGAACTCGACTTCGGTCGCGTTCGATTTAT
TCAACAAAGCCACG) and 3-m157-Kan and plasmid pACYC177 as the tem-
plate DNA. This fragment was subsequently inserted into MCMV BACs pSM3fr
and pSM3fr-FRT, respectively, by homologous recombination in E. coli as de-
scribed previously (49), generating recombinant MCMV BACs pm157 and
pm157-FRT. These genomes lack most parts of the m157 gene, including the
ATG start codon (nt positions 216291 to 216874).
Reinsertion of the m157 gene, including its promoter, at an ectopic position
into the m157 deletion genome. For reinsertion of the m157 ORF including its
promoter and an additional poly(A) signal from BHG into MCMV BAC
pm157-FRT at the ectopic position between genes m16 and m17, a linear DNA
fragment that contains these elements and an additional Zeocin resistance gene
was generated by PCR with primers 5-m157-Zeo-m16/17 (5-CCCTCTTAATC
ATGACAATTATAAGTGTCTTATACGCAATACTTTTATCATAATACAT
GTGGAATTGTGAGC) and 3-m157-Zeo-m16/17 (5-GAGGAATAGGAATA
ACTCACCACCGATTTCAGCGTCTGCCCCAAGTCTGATTAGCACGTGT
CAGTCCT) and plasmid pori6k-m157-pA as the template DNA. After
homologous recombination of this fragment with pm157-FRT in E. coli, rever-
tant MCMV BAC pm157rev was generated. The correct insertion of the m157
gene, including its promoter, at this ectopic position was confirmed by restriction
pattern analysis and sequencing with primers M157-1 (5-TGTTGACCGCCAT
CTGTTCTTGA), M157-2rev (5-GGTAAGATTAATATTCAAGGATCA),
and M157-3 (5-GGATTGAAAATTGTTACAGCACG) (data not shown).
Reconstitution of virus mutants from recombinant BACs. By transfection of 2
g of the corresponding MCMV BAC DNA into MEFs, mutants m157-
MCMV and m157-FRT-MCMV and revertant virus m157Rev-MCMV were
reconstituted as previously described (51).
Northern blot analysis. NIH 3T3 fibroblasts were infected at a multiplicity of
infection (MOI) of 3 with m157, w.t. MCMV, or m157Rev, and total RNA was
isolated 6 and 24 h postinfection with the TriZol reagent (Invitrogen) in accor-
dance with the manufacturer’s instructions. An [-32P]dCTP-labeled DNA probe
specific for 528 bp of the m157 gene (nt positions 216350 to 216878, according to
reference 33) was generated with the nick translation kit from Amersham (Am-
ersham Biosciences Europe) in accordance with the manufacturer’s instructions.
Three micrograms of total RNA from each sample of virus-infected cells was
separated on a denaturing formaldehyde gel, blotted to a nylon membrane, and
hybridized with the [-32P]dCTP-labeled DNA probe for detection of m157-
specific mRNA transcripts.
Animals. BXD-8/Ty (H-2b), 129/SvJ (H-2b), and C57BL/6 RAG1/ (H-2b)
mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). All of
the mice used in this study, including congenic inbred BALB.B6-Cmv1r (H-2d)
and inbred C57BL/6 (H-2b) and BALB/c (H-2d) mice, were housed and bred
under specific-pathogen-free conditions at the Central Animal Facility of the
Medical Faculty, University of Rijeka, in accordance with the guidelines con-
tained in the International Guiding Principles for Biomedical Research Involving
Animals. The Ethical Committee at the University of Rijeka approved all of the
animal experiments described here. C57BL/6 RAG1/ (H-2b) mice were main-
tained under specific-pathogen-free conditions in the animal facility of the Wash-
ington University School of Medicine, and the experiments conducted with these
mice were in accordance with institutional guidelines for animal care and use.
Six- to eight-week-old female mice were used in all of the experiments.
Infection conditions, detection of infectious MCMV in tissues, and statistical
evaluation. Mice were injected intravenously with 5  105 (Ly49H mice) or 2
 105 (Ly49H mice) PFU of tissue culture-grown recombinant virus or w.t.
MCMV in a volume of 500 l of diluents. Organs were collected 3 days after
infection, and viral titers were determined with a standard assay of viral plaque
formation on MEFs (34). Each experiment shown here is representative of at
least three independent experiments. The statistical significance of differences
between experimental groups was determined by the Mann-Whitney exact rank
test. Viral titers (from groups x and y) were considered significantly different for
P (x versus y)   	 0.05 (one sided), where P is the observed probability value
and  is a selected significance level.
Depletion of NK cell subsets in vivo. Depletion of NK1.1 cells was done with
monoclonal antibody (MAb) PK136 (20) at a concentration of 1 mg per mouse
by intraperitoneal inoculation 24 to 2 h before infection. The efficacy of depletion
was assessed by cytofluorometric analysis of spleen cells with phycoerythrin
(PE)-conjugated antibodies to mouse NK1.1 (BD Bioscience Pharmingen, San
Diego, Calif.). Depletion of Ly49C/I NK cell subsets was performed with MAb
5E6 (31) at a concentration of 150 g per mouse, and depletion of Ly49C/H/I
NK cell subsets was performed with MAb 1F8 (9) at a concentration of 150 g
per mouse by intraperitoneal inoculation 24 h before infection.
Staining of intracellular IFN-. An in vitro assay to detect gamma interferon
(IFN-
) production was performed as previously described (42). Briefly,
C57BL/6 RAG1/ splenocytes were cocultured for 12 h with IC-21 cells that
were either uninfected or infected for 24 h at an MOI of 5 with m157 mutant,
m157Rev, or w.t. MCMV. Brefeldin A (BD Bioscience Pharmingen) was added
for the last 11 h of coincubation. Cells were first surface stained with biotinylated
3D10 (-Ly49H) (41) and then stained with PE-streptavidin and allophycocya-
nin-PK136. Cells were fixed and permeabilized with the Cytofix/Cytoperm kit
(BD Bioscience Pharmingen) in accordance with the manufacturer’s instructions.
Intracellular IFN-
 was stained with fluorescein isothiocyanate-XMG1.2 (BD
Bioscience Pharmingen) in the permeabilization buffer. Cells were analyzed with
a FACScalibur cytometer (BD Biosciences, San Jose, Calif.) gating on the
NK1.1 CD3 populations.
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RESULTS
Generation of MCMV mutants. To investigate the signifi-
cance of the m157 gene product for virus control in vivo, two
independent MCMV mutants were constructed. First, mutants
with a targeted deletion of the m157 gene (m157 and m157-
FRT) were prepared (Fig. 1). In vitro and in vivo testing in the
lungs, spleens, and livers of BALB/c and C57BL/6 mice at day
3 postinfection revealed no difference between m157 and
m157-FRT (data not shown). In the experiments described
here, only m157 was used. Thereafter, a revertant virus
(m157Rev) was constructed. Rather than reconstructing the
w.t. situation, in the revertant virus the m157 gene was rein-
troduced at an ectopic position between ORFs m16 and m17 of
the MCMV genome to selectively study the effect of the m157
ORF. All mutants were derived from parental MCMV BAC
pSM3fr, which has w.t. MCMV properties in vitro and in vivo
(50). The correct mutagenesis of the resulting m157 and
m157-FRT strains, as well of the m157Rev MCMV strain,
was confirmed by restriction pattern analysis and sequencing of
the m157 genome region.
No phenotype of m157 and m157Rev in cell culture. Mul-
tistep growth curves of recombinant and w.t. MCMVs served
to assess whether deletion of the m157 gene and its ectopic
reinsertion affect virus growth in cell culture. After infection of
primary BALB/c MEFs at 0.01 PFU per cell, the replication of
m157 and the m157Rev was indistinguishable from that of
w.t. MCMV (Fig. 2). These results indicated that the m157
gene product is dispensable for virus growth in fibroblasts and
that ectopic reinsertion of this gene between MCMV ORFs
m16 and m17 does not compromise viral growth in vitro.
m157 gains virulence in Ly49H mice through loss of NK
cell-mediated control. Replication of MCMV in vivo during
the early period after infection inversely correlates with the
ability of mouse strains to mount an effective NK cell response,
which is controlled by the Ly49h locus (15). The MCMV pro-
tein encoded by the m157 gene is the only ligand for the Ly49H
FIG. 1. Genome structure of recombinant MCMVs. The HindIII cleavage map of the MCMV (Smith strain) genome is shown at the top.
Deletion and insertion of the m157 gene, respectively, were achieved by homologous recombination between the parental MCMV BACs and a
linear DNA fragment containing the desired sequence, a kanamycin resistance gene (Kn), and flanking homologies to the target site in the viral
genome. The deletion genome pm157 was generated by homologous recombination of the linear DNA fragment and w.t. MCMV BAC pSM3fr.
An independent m157 genome was constructed as follows. First, a 48-bp FRT site (grey box) was inserted into the intergenic region between
genes m16 and m17, generating pSM3fr-FRT, to prove that insertion of sequences at this positions does not interfere with virus replication. In a
second mutagenesis step, the m157 gene was deleted from pSM3fr-FRT, generating the second independent m157 deletion genome, pm157-FRT.
Finally, the m157 gene, including its native promoter, was reinserted into pm157-FRT at the ectopic positions between genes m16 and m17,
thereby removing the FRT site. The names of the MCMV BACs are indicated on the left. Recombinant viruses were reconstituted by transfection
of the recombinant MCMV BACs into permissive MEFs. The names of the corresponding reconstituted viruses are given on the right.
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receptor that has been identified so far (2, 42). To test whether
the m157 protein is the only MCMV protein interacting with
Ly49H, we used the m157 virus. C57BL/6 (Ly49H) mice
(Fig. 3, top) and congenic BALB.B6-Cmv1r mice (Fig. 3, bot-
tom) were injected with m157 or w.t. MCMV, and virus titers
in their organs were determined 3 days later. The spleens and
lungs of mice infected with m157 showed significantly higher
virus titers than did those of mice infected with w.t. MCMV.
Consistent with published data (6, 52, 53), depletion of NK
cells by anti-NK1.1 MAbs increased the virus titers in mice
infected with w.t. MCMV, whereas it had no effect on the virus
titers in the spleens and lungs of mice infected with m157. We
concluded that m157 virus is resistant to NK cell control in
vivo and that there is no other viral ligand for Ly49H encoded
by the MCMV genome.
Remarkably, NK cells were efficient in limiting virus repli-
cation in liver irrespective of the presence or absence of the
m157 gene. This finding is in line with previously published
data on the protective effect of the Cmv1 (Ly49h) locus in the
spleen but not in the liver (5, 37, 44). Interestingly, contrary to
the MCMV titer in the liver and similar to that in the spleen,
the MCMV titer in the lungs was also controlled by the Ly49H
NK cell activation receptor.
Reintroduction of the m157 gene reverses the susceptibility
of MCMV to NK cells. To confirm that resistance of mutant
virus to NK cells in vivo is solely due to lack of the m157
protein and no other unwanted effect in m157, we compared
the abilities of m157, m157Rev, and w.t. MCMVs to induce
activation of Ly49H NK cells. Splenocytes derived from
C57BL/6 RAG1/ mice were incubated for 12 h with
FIG. 2. In vitro growth of recombinant viruses. BALB/c MEFs
were infected with m157, m157Rev, or w.t. MCMV at 0.01 PFU per
cell. Supernatants were harvested at the indicated time points after
infection, and virus titers were determined.
FIG. 3. Deletion of the m157 gene abolishes MCMV susceptibility to NK cell-mediated control in Ly49H mice. Undepleted (open circles) or
NK1.1-depleted (shaded circles) C57BL/6 and congenic BALB.B6-Cmv1r mice were injected intravenously with 5  105 PFU of m157 or w.t.
MCMV. Three days after infection, the virus titers in the spleen, lungs, and liver were determined by standard plaque assay. Titers in individual
mice (circles) and median values (horizontal bars) are shown. Virus titers were calculated per organ in the spleen and lungs and per gram of liver.
The differences in viral titers between undepleted and NK cell-depleted groups of mice are shown by shaded areas. There were significant
differences (P  0.025) in virus titers between the groups of undepleted mice infected with m157 and w.t. MCMV in the spleen and lungs.
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MCMV-infected IC-21 cells, and the frequency of Ly49H
IFN-
-secreting cells was measured (Fig. 4A). The incubation
of splenocytes with w.t. MCMV- or m157Rev-infected IC-21
cells resulted in a comparable expansion of Ly49H IFN-
-
secreting cells (11.1 and 15.6%, respectively). IC-21 cells in-
fected with m157 failed to activate Ly49H cells, and the
percentage of activated Ly49H NK cells was the same as in
cultures incubated with uninfected IC-21 cells. These findings
confirm previously published data, obtained by anti-Ly49H
blockade and reporter cell assays, that showed that the isolated
m157 protein is crucial for the activation of Ly49H NK cells
(2, 42). The results presented here extend the above studies to
the situation found during virus infection. As shown in Fig. 4B,
reintroduction of the m157 gene into the m157 genome also
reversed the sensitivity of the virus to NK cell control in vivo.
This is illustrated by the fact that the titers of the m157Rev
virus in C57BL/6 mice were significantly lower than those of
m157. Furthermore, the depletion of NK cells increased the
titer of m157Rev whereas, consistent with the data presented
in Fig. 3, m157 remained resistant to NK cell control. The
reconstitution of viral sensitivity to NK cells essentially con-
firmed the role of the m157 gene. Still, the in vivo function of
the gene in m157Rev was not fully restored. This is probably
due to the fact that the bona fide promoter of m157 was
transferred together with the ORF. Therefore, other se-
quences modulating gene expression may be lacking, and in-
deed, Northern blot analysis revealed that the m157 transcripts
appear earlier in m157Rev-infected cells and peak later in
w.t.-infected cells (see supplemental material). This difference
in the activity of ectopic m157 might explain the variance in
virus sensitivity to NK cells in vivo.
m157 lacks a phenotype in C57BL/6 mice depleted of
Ly49H NK cells and in mice lacking the Ly49H receptor. To
address the role of the Ly49H NK cell subset in the control of
MCMV infection and the role of the m157 protein, C57BL/6
mice were injected with MAb 5E6 (Ly49C/I), 1F8 (Ly49C/
FIG. 4. NK cell activation and reversal of susceptibility to NK cell control by reintroduction of the m157 gene. (A) C57BL/6 RAG1/
splenocytes were incubated for 12 h (1 h without brefeldin A and 11 h with brefeldin A) with IC-21 cells that were either uninfected or infected
(MOI 	 5, 24 h) with m157, m157Rev, or w.t. MCMV. Cells were stained with biotinylated anti-Ly49H, followed by PE-streptavidin and
allophycocyanin–anti-NK1.1. The cells were fixed, permeabilized, and stained with fluorescein isothiocyanate–anti-IFN-
 antibody. Data represent
NK1.1 cells. The values are the percentages of cells within the quadrants. (B) Undepleted (open circles) or NK1.1-depleted (shaded circles)
C57BL/6 mice were injected intravenously with 5  105 PFU of m157, m157Rev, or w.t. MCMV, and virus titers in the spleen and lungs were
determined 3 days after infection. Titers in individual mice (circles) and median values (horizontal bars) are shown. The differences in viral titers
between undepleted and NK cell-depleted groups of mice are shown by shaded areas. There were significant differences (P  0.025) in virus titers
between the groups of undepleted mice infected with m157 and m157Rev and between the groups of undepleted mice infected with m157 and
w.t. MCMV.
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H/I), or PK136 (NK1.1) prior to infection with either w.t. or
m157 MCMV. Depletion of 1F8 cells, but not 5E6 cells, in
mice infected with w.t. MCMV led to an increase in virus titers
comparable to the effect of NK1.1 cell depletion. This indi-
cates that other NK cell subsets contribute very little, if at all,
to virus control (Fig. 5A). In accordance with the data pre-
sented in Fig. 3, in mice infected with m157, depletion of the
Ly49H subset did not increase the virus titers. Therefore, the
m157 effect on NK cell activation was mediated solely by the
Ly49H NK cell subset, thus confirming previous studies (5,
9).
The BXD-8 mouse strain is a recombinant inbred strain
derived from C57BL/6 (Ly49H) and DBA/2 (Ly49H) pro-
genitor strains (45). Although BXD-8 mice possess the entire
natural killer gene complex from C57BL/6 mice, they are sus-
ceptible to MCMV infection because of a lesion in the Ly49h
gene (5, 23). For that reason the m157 protein should play no
role in NK cell-mediated virus control in these mice. Indeed, 3
days after infection, no differences in virus titers between the
group of mice infected with m157 and that infected with w.t.
MCMV were observed (Fig. 5B). Furthermore, NK depletion
had no influence on virus titers, confirming that in the absence
of Ly49H the m157 protein plays no role in virus control.
Weak phenotype of m157 in BALB/c and 129/SvJ mice. We
tested the role of the m157 protein in mice lacking the Ly49H
but expressing the Ly49I NK cell receptor. 129/J mice do not
contain Ly49H or other NK cell activation receptors that rec-
ognize m157 (2). However, 129/J mice express the inhibitory
NK cell receptor Ly49I (26). The m157 protein binds to 129/J
NK cells but not to NK cells of BALB/c mice in vitro (2). If the
in vitro conditions reflect the situation in vivo, m157 should
be more attenuated in 129/J mice than in BALB/c mice. To test
this, BALB/c and 129/SvJ mice were injected with m157 or
w.t. MCMV and virus titers were tested. Remarkably, there
was no difference in the reactivities of these two mouse strains.
However, there was a small but statistically significant differ-
ence (P  0.025) between m157 and w.t. MCMV control in
the spleen, indicating a certain degree of attenuation (Fig. 6).
Nevertheless, we concluded that the presence or absence of the
m157 gene has no strong phenotype in mice expressing the
Ly49I NK receptor.
NK response to m157 in C57BL/6 mice is prevented by
viral evasion genes. MCMV has several NK silencing genes, of
which only m152 and m144 have been characterized (13, 22,
25). To show the impact of viral silencing genes in a Ly49H
strain, we compared m157 with w.t. MCMV and a virus in
which in addition to m157, 14 other genes, including m152,
were deleted (Fig. 7). W.t. MCMV is strictly controlled by NK
cells, and the virus grows only after NK cell depletion. m157
lacks the NK activation via m157-Ly49H, and therefore NK
depletion has no phenotype. The MS94.5 virus lacks m157
and, in addition, 14 other genes, including m152, that prevent
NK cell activation by down-modulating NKG2D ligands (22,
25). We now have evidence that at least one more MCMV
FIG. 5. Ly49H NK cells play no role in control of m157 virus.
(A) C57BL/6 mice were depleted with MAb 5E6 (Ly49 C/I), 1F8
(Ly49 C/H/I), or PK136 (NK1.1) and injected intravenously with 5
 105 PFU of m157 and w.t. MCMV. Virus titers in the lungs were
determined 3 days after infection. Data represent the mean value 
the standard deviation of four or five mice. Depletion with MAb 1F8
or PK136 resulted in a significant increase (P  0.025) in the w.t.
MCMV titer. (B) Recombinant BXD-8 mice were injected with 2 
105 PFU of m157 and w.t. MCMV, and virus titers in the spleen and
lungs were determined 3 days after infection. Titers in individual mice
(circles) and median values (horizontal bars) are shown.
FIG. 6. Control of m157 virus in BALB/c and 129/SvJ mice.
BALB/c and 129/SvJ mice were injected with 2  105 PFU of m157
and w.t. MCMV, and virus titers in the spleen and lungs were deter-
mined 3 days later. Titers in individual mice (circles) and median
values (horizontal bars) are shown. There were significant differences
(P  0.025) in virus titers in spleen between groups of mice infected
with m157 and w.t. MCMV.
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gene, in addition to m152, can down-modulate ligands for the
NKG2D receptor (S.J., unpublished data). This inhibitory ef-
fect is present in the m157 virus, and therefore the m157
virus grows to a higher titer than the MS94.5 virus, which has
lost this NK silencing gene(s). Deletion of NK cells abolishes
this type of control, resulting in identical titers of the MS94.5
and m157 viruses. This situation is comparable to the situa-
tion in Cmv1s mice after infection in the absence or presence
of the m152 gene (22). Therefore, in the presence of a number
of additional viral silencing genes the effect of the m157-Ly49I
interaction is not expected to have a strong impact.
DISCUSSION
Viruses affect NK cell control by providing viral ligands that
bind NK cell receptors. Depending on whether these receptors
are activating or inhibitory, the resulting NK function is mod-
ulated (29). The second type of NK cell modulation affects
cellular ligands for NK cell receptors that are regulated by
infection or stress (3, 22, 25). Two MCMV genes are thought
to encode ligands for NK cell receptors, m144 and m157, but
only the cognate NK cell receptor for the m157 protein,
Ly49H, has been identified (2, 42). The interaction between
Ly49H and the m157 protein is a unique situation and contrib-
utes to MCMV resistance in C57BL/6 mice, which express the
Ly49H NK cell activation receptor. In previous studies the
ligand-receptor interaction was demonstrated by expressing
the isolated viral ligand (2, 42). By deleting m157 from the
MCMV genome, we show that m157 indeed is the only MCMV
ligand for Ly49H. Accordingly, in congenic mice lacking the
Ly49H receptor (BXD-8), as well as in mice depleted of
Ly49H NK cells, deletion of this gene from the virus has no
phenotype. Ly49H mice, after infection with m157, lose
their MCMV-encoded resistance phenotype.
m157 also serves as a ligand for the inhibitory NK receptor
Ly49I in the MCMV-susceptible 129/J strain, and it also binds
to NK cells of other MCMV-sensitive strains (1). Therefore,
m157 is seen as an inhibitory NK cell ligand and Ly49H mice
are considered an exception to the rule. However, no experi-
ments in which NK cell function is blocked through m157-
Ly49I have been published. Loss of NK cell activation can be
studied in the context of virus infection when the virus either
expresses or lacks the gene of interest. However, when we
studied the effect of m157 deletion in the 129/SvJ strain no
vigorous phenotype became apparent. A certain degree of
virus attenuation was noticed in both BALB/c and 129/SvJ
mice. Considering that the m157 protein binds to the Ly49I
allelic form of 129/J but not of BALB/c mice (2), it is not clear
whether this effect is related to the m157-Ly49I interaction. A
strong signal was not to be expected, since in comparison to
NK cells from the C57BL/6 strain only a minority of NK cells
from 129/J mice binds m157 but does not lyse m157 targets in
vitro (2).
The absence of NK activation in Ly49H mice infected with
m157 provided the opportunity to demonstrate the function
of other viral genes inhibiting NK cell function. These genes
act by down-modulating NKG2D ligands similarly to the func-
tion of m152 (22, 25). There is another not yet identified
gene(s) in the left end of the genome (28), and we have evi-
dence of at least one additional gene elsewhere (U.H.K. and
S.J., unpublished data). Most NK cells express NKG2D recep-
tors (18). Therefore, the loss of one silencing signal from a
chorus of several is difficult to detect. This situation is similar
to that of the genes modulating MHC class I expression, in
which identification of the three genes involved (m04, m06,
and m152) had to precede the construction of virus mutants
that lack or express class I modulating functions in all possible
combinations (49). In addition, deletion of the viral gene that
down-modulates a ligand for an activating NK cell receptor has
an immediate effect on NK control, since virus infection up-
regulates stress-induced ligands (7, 11). On the other hand,
deletion of a viral ligand for an inhibitory NK cell receptor
should not have a strong phenotype, especially if the stress-
induced activating ligands are down-modulated at the same
time.
Our study also confirms and extends the known complexity
of NK cell control in different organs (30, 44). The Cmv1 locus
has been described as a host resistance locus that regulates NK
cell responses during acute MCMV infection in the spleen
(37). Accordingly, m157 lacks this type of control. In addi-
tion, we show here for the first time that, akin to virus control
in the spleen, Ly49H NK cells also mediate MCMV control
in the lungs. Additional evidence for this is provided by
C57BL/6 mice depleted of Ly49H NK cells, in which the titer
of w.t. MCMV in the lungs reached a level comparable to that
after depletion of NK1.1 NK cells. In contrast, MCMV con-
trol in the liver appears to be independent of m157-Ly49H
interaction. This finding is in accordance with the minimal
effects of anti-Ly49H MAbs on the virus titer in the liver (5),
pointing at a different type of NK control of MCMV in that
organ (30, 44). After MCMV infection, NK cells pass through
two different stages of activation. The first, nonspecific phase,
during the first 2 days after MCMV infection, is characterized
by IFN-
 production and NK cell proliferation, irrespective of
FIG. 7. NK cell response against m157 in C57BL/6 mice is pre-
vented by viral evasion genes. Undepleted (open circles) or NK1.1-
depleted (shaded circles) C57BL/6 mice were injected intravenously
with 5  105 PFU of w.t., m157, or MS94.5 MCMV, and virus titers
in the lungs were determined 3 days after infection. Titers in individual
mice (circles) and median values (horizontal bars) are shown. The
differences in viral titers between undepleted and NK cell-depleted
groups of mice are shown by shaded areas. There were significant
differences (P  0.025) in virus titers between the groups of unde-
pleted mice infected with m157 and MS94.5 and between the
groups of undepleted mice infected with m157 and w.t. MCMV.
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Ly49H expression, while in the second, specific phase, there is
a selective proliferation of Ly49H NK cells (12). This early
activation of NK cells may be sufficient to control virus infec-
tion in the liver but not in the spleen and lungs. The mode by
which NK cells mediate their antiviral effector function also
differs between the liver and spleen. While in the spleen NK
cells act via a cytolytic mechanism, in the liver MCMV is
controlled by cytokines including IFN-
 produced by NK and
NKT cells (30, 44). In perforin-deficient C57BL/6 mice, no
differences between m157 and w.t. MCMV titers in the
spleen were observed, which suggests that Ly49H-positive cells
mediate their effect almost exclusively via a perforin-depen-
dent pathway (I.B., unpublished data).
The MCMV genome harbors genes, in addition to m152
(22), whose products down-modulate NKG2D ligands, also in
mice expressing Cmv1r (Ly49h) (S.J., unpublished). However,
this inhibition of NK cell activation is overridden by NK acti-
vation through m157, which makes these mice an exception to
the rule. It has been proposed that natural isolates from wild
mice, depending on the presence or absence of the Ly49H
receptor, are expected to be variable in the m157 gene (1, 35).
Indeed, this has been recently demonstrated by Voigt et al.,
who reported that most of the MCMV strains they isolated
from wild mice possessed a specific mutation of the m157 gene
(48). Furthermore, this study provides evidence that NK cells
can exert sufficient immunological pressure on MCMV that it
undergoes rapid and specific mutation in the m157 gene re-
gion. Accordingly, we have been studying immunodeficient
C57BL/6 mice that rely on NK functions to survive MCMV
infection. Under these selective conditions, virus mutants arise
that indeed do not respond to the Ly49H receptor (R. A.
French, T. J. Pingel, M. Wagner, I. Bubic, L. Yang, S. Kim,
U. H. Koszinowski, S. Jonjic, and W. M. Yokoyama, submitted
for publication).
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